Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
Saturday, February 24, 2024BrainStorm Cell Therapeutics Inc a leading developer of adult stem cell therapeutics for neurodegenerative diseases today announced that it has
MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
Friday, February 23, 2024MAIA Biotechnology Inc a clinicalstage biopharmaceutical company developing targeted immunotherapies for cancer today announced that enrollment is now complete in its Phase THIO gotomarket clinical trial evaluating THIO
Gracell Biotech announces official merger with AstraZeneca Group
Friday, February 23, 2024Gracell Biotech Group is a A global clinicalstage biopharmaceutical company dedicated to developing innovative cell therapies to treat cancer and autoimmune diseases Today the company announced that it has officially completed the
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
Friday, February 23, 2024Arcturus Therapeutics Holdings Inc a global latestage clinical messenger RNA medicines company focused on the development of infectious disease vaccines
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
Thursday, February 22, 2024Vaccinex Inc a clinicalstage biotechnology company pioneering a differentiated approach to treating Alzheimers disease and cancer through the inhibition of SEMAD announces that it has entered into eight new antibody discovery agreements
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
Thursday, February 22, 2024Regeneron Pharmaceuticals Inc today announced that the US Food and Drug Administration has accepted for Priority Review the Biologics License Application BLA for linvoseltamab to treat adult patients
FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant Diffuse Glioma
Wednesday, February 21, 2024Servier a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves today announced the FDA filing acceptance and priority review for a New Drug Application
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
Wednesday, February 21, 2024Avidity Biosciences Inc a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates today
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
Wednesday, February 21, 2024Evaxion Biotech AS a clinicalstage TechBio company specializing in developing AIImmunology powered vaccines announces the successful completion of the initial phases of its vaccine collaboration with MSD
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences
Wednesday, February 21, 2024Precision BioSciences Inc an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits including gene elimination
